Extended Data Fig. 4: Characterization of SnCs in the liver from STAM mice and additional evaluations of 753b treatment on STAM mice.
A. A cartoon indicates distribution of zone 1, 2, and 3 hepatocytes in liver lobules along with blood flow across the periportal to pericentral axis. Periportal hepatocytes are in zone 1 that consists of portal veins, hepatic arteries, and bile ducts. B-C. SA-β-gal staining was combined with immunohistochemistry to characterize types of SnCs in the livers from STAM mice 8 weeks after STZ and 4 weeks after HFD. Antibodies against the pericentral hepatocyte marker Cyp2E1 (B), periportal hepatocyte marker GP6Cα (C), hepatocyte marker HNF4α (D), and biliary epithelial cell marker CK19 (E) were used for the stainings. Representative images of the stainings are presented on the left (scale bar = 100 µm) and higher magnification images of the marked area on the left images are presented on the right for C-E. Data presented in A-E are from one representative experiment and three independent experiments were performed with similar results. F. The levels of Cdkna1 mRNA in the tumor free liver tissues from VEH-treated and 753b-treated STAM mice on P150. The data are presented as means ± SEM (n = 5 mice/group) and were analyzed by a two-tailed, unpaired Student’s t-test. G. The levels of selected SASP mRNA in the tumor free liver tissues from STAM mice on P150. The data are presented as means ± SEM (n = 2 and 3 mice for VEH and 753b group, respectively) and were analyzed by a two-tailed, unpaired t-tests. H. Photo of reprentative VEH-treated and 753b-treated STAM mice on P150. I. Whole body weight of STAM mice on P150. Data are presented as means ± SEM (n = 5 mice per group) and were analyzed by a two-tailed, unpaired Student’s t-test. J. Blood levels of glucose in VEH- and 753b-treated STAM mice after IP injection of insulin one week before the termination of the experiment on P150. Data are presented as means ± SEM (n = 5 mice per group) and analyzed by two-way ANOVA.
